Robert Ernest William Hancock OC OBC FRSC (born March 23, 1949) is a Canadian microbiologist and University of British Columbia Killam Professor of Microbiology and Immunology, an Associate Faculty Member of the Wellcome Trust Sanger Institute, and a Canada Research Chair in Health and Genomics.

Over his career he has published more than 800 papers and reviews, has 72 patents awarded, and is an ISI highly cited author in Microbiology with more than 113,000 citations and an h-index of 168.

[7][8] To understand the role of these peptides as modulators of the immune system he developed InnateDB, NetworkAnalyst and MetaBridge as tools to enable systems/network biology studies and insights.

[9] Currently Hancock and his lab’s research interests include small cationic peptides as novel antimicrobials, broad-spectrum anti-biofilm agents, and modulators of innate immunity, the development of novel treatments for antibiotic resistant infections and inflammation, the systems biology of innate immunity, inflammatory diseases and Pseudomonas aeruginosa, and antibiotic uptake and resistance.

CAIN was formed with the purpose of leveraging innovative approaches and expertise to solve the expanding health crisis caused by Antimicrobial Resistance (AMR) infections.